indacaterol/glycopyrronium
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
... of indacaterol/glycopyrronium (IND/GLY) has proven to be an effective treatment option for patients with COPD demonstrating significant improvements in lung function [8], dyspnea [9], quality of life [3], ...
8
Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
... In this study, the efficacy of a maintenance combination therapy with indacaterol/glycopyrronium versus tiotro- pium on IOS parameters in patients with moderate to severe COPD was studied. We demonstrated ...
8
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
... The effectiveness of the indacaterol/glycopyrronium com- bination in the treatment of severe COPD is supported by RCTs and meta-analysis. In several studies also PROs were evaluated, including patient’s ...
6
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
... Methods: Data were analyzed from three 26-week studies comparing indacaterol/ glycopyrronium (IND/GLY) with tiotropium (TIO) or salmeterol/fluticasone (SFC). Two definitions of CID were used; each was a ...
13
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
... IND/GLY: indacaterol/ glycopyrronium; LABA: long-acting β 2-adrenergic agonist; LAMA: long-acting muscarinic antagonist; mMRC: modified Medical Research Council; NMB: net monetary benefit; NNT: Number ...
10
<p>Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach</p>
... Indacaterol/glycopyrronium (IND/GLY) was the fi rst LABA/LAMA combination to be approved for the treatment of COPD and consequently, its cost-effectiveness has been studied extensively, 16 – 19,22,23 ...
11
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
... with indacaterol/glycopyrronium (IND/ GLY) was similarly efficacious in women and men with moderate-to-very-severe COPD in terms of improvement in lung function and health status, and reduction in dys- pnea ...
8
Efficacy and safety of indacaterol/glycopyrronium fixed dose combination in mild to moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
... once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μ g fixed-dose LABA/LAMA combination results in an improved lung function in symptomatic patients with mild-to-moderate COPD who switch from once-daily ...
6
Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study
... The combination of the LABA indacaterol acetate (IND) and the LAMA glycopyrronium bromide (GLY) is presently available as once daily (o.d.) treatment for pa- tients with chronic obstructive pulmonary ...
5
The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study – the FAVOR study
... Consistent with other clinical trials, irrespective of treat- ment sequence, in the FAVOR study, IND/GLY showed statistically significant improvement in FEV 1 1 h post- i[r] ...
9
Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)
... The study was powered on number of steps, and it is important, therefore, that there was a significant im- provement with IND/GLY over placebo for this param- eter. A previous study has suggested that every additional ...
10
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study
... of indacaterol (IND)/glycopyrronium (GLY) 110/50 μg once daily (od) compared with GLY 50 μg od, IND 150 μg od, open-label tiotropium (TIO) 18 μg od, and ...
9
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
... The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy classifies patients with COPD into GOLD groups A to D, based on individual risk, in terms of airflow limi[r] ...
9
A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
... Exploratory objectives were to assess the effect of IND/GLY, compared with placebo, on sleep quality measured by the Medical Outcomes Study (MOS) Sleep Scale and the COPD and Asthma Sl[r] ...
12
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
... GLY, glycopyrronium; HR, hazard ratio; ICS, inhaled corticosteroid; IEC, Independent Ethics Committee; IND, indacaterol; IRB, Institutional Review Board; LABA, long-acting β 2 -agonist; LAMA, long-acting ...
11
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
... A once-daily (q.d.) combination of indacaterol and glyco- pyrronium (IND/GLY) was effective and well tolerated in patients with moderate-to-severe COPD in several phase III trials [3, 4]. Such pivotal trials are ...
9
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
... monocomponents indacaterol, glycopyrronium, and tiotropium (Table 4 and Figure ...versus indacaterol, glyco- pyrronium, and tiotropium, respectively ...the glycopyrronium-indacaterol ...
13
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
... Background: The FLAME study compared once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μ g with twice-daily salmeterol/fluticasone (SFC) 50/500 μ g in symptomatic patients with [r] ...
10
Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
... once-daily indacaterol/ glycopyrronium seems to be safe and well tolerated in patients with ...(indacaterol, glycopyrronium, and tiotropium) and fixed-combination long-acting β 2 ...
8
<p>Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA</p>
... Background: Current pharmacological therapies for COPD improve quality of life and symptoms and reduce exacerbations. Given the progressive nature of COPD, it is arguably more important to understand whether the ...
16